Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator dictionary.testing.TypeOfStudy dictionary.testing.PhasesOfClinicalTrialsForDrugs
N202512084 A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Safety and Efficacy of MS-20 (Symbiota®) Nasal Irrigation for the Treatment of Radiation-Induced Rhinosinusitis (RiRS) in Head and Neck Cancer Patients Post-Radiotherapy. New Drug Phase Ⅱ
N202512085 EASi-HF Preserved – A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) ≥40% New Drug Phase Ⅲ
N202512112 Clinical Evaluation of a Combination Therapy of L-Arginine, N-Acetylcysteine, and Sildenafil for the Treatment of Erectile Dysfunction New Drug (New Indication) Academic Research
N202512113 A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants with Metabolic Dysfunction-Associated Steatotic Liver Disease who are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes) New Drug Phase Ⅲ
N202601007 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma New Drug Phase Ⅲ
N202601028 A Randomized, Double-Blinded, Vehicle-Controlled, Parallel, Phase II Study to Evaluate the Efficacy and Safety of Topical BB-101 (rhNEGF) for the Treatment of Diabetic Lower Leg and Foot Ulcers New Drug Phase Ⅱ
N202601029 Randomized, Two-Cohort, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy In Participants with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy New Drug Phase Ⅲ
N202601082 An Open-label, Randomized, and Crossover Bioequivalence Study of Ezetimibe/Rosuvastatin 10/20 mg Film-Coated Tablet in Healthy Subjects under Fasting Conditions Bioavailability / Bioequivalence (BA/BE) NA
N202601084 An Open-Label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab Plus Carfilzomib Versus Standard of Care Combination Regimens in Patients with Relapsed/Refractory Multiple Myeloma New Drug Phase Ⅲ
N202601085 HepatoWell.ai software - formative and fidelity test pilot study project New Medical Device NA
1 2 37 38 39 40 41 42 43 51 52 / 52

TOP